58. Semaglutide for Alcohol Use Disorder (RCT)58. Semaglutide for Alcohol Use Disorder (RCT)
Addiction Medicine Journal Club
This episode explores a study on semaglutide for alcohol use disorder and discusses new benzodiazepine tapering guidelines and Sublocade uses.
40:50•14 Apr 2025
Semaglutide: A New Hope for Alcohol Use Disorder?
Episode Overview
- Semaglutide shows promise in reducing alcohol consumption and cravings.
- New benzodiazepine tapering guidelines acknowledge long tapering periods.
- Sublocade can now be administered in more body sites and with less lead time.
- The cost of semaglutide remains a significant barrier to widespread use.
- The study highlights the need for more effective treatments for alcohol use disorder.
“Our current FDA-approved medications really fail to meet the needs of my patients with alcohol use disorder.”
Ever wondered if a diabetes drug could help with alcohol use disorder? This episode of the Addiction Medicine Journal Club dives into a fascinating study on semaglutide, typically used for diabetes and weight loss, and its potential in treating alcohol use disorder. Hosts Dr. Sonya Del Tredici and Dr. John Keenan break down the first randomized controlled trial on this topic, offering insights into the study's methodology, results, and implications for future treatments.
They also touch on benzodiazepine tapering guidelines and new ways to use Sublocade, making this episode a treasure trove of information for anyone interested in addiction medicine. With their blend of professional expertise and casual banter, Sonya and John make complex medical research accessible and engaging. If you're curious about cutting-edge treatments for alcohol use disorder or want to stay updated on the latest in addiction medicine, this episode is a must-listen.
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.